446 related articles for article (PubMed ID: 273923)
21. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Parker CJ; Baker PJ; Rosse WF
J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
23. Control of the amplification convertase of complement by the plasma protein beta1H.
Weiler JM; Daha MR; Austen KF; Fearon DT
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
[TBL] [Abstract][Full Text] [Related]
24. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.
Pangburn MK; Müller-Eberhard HJ
Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.
Weiler JM; Yurt RW; Fearon DT; Austen KF
J Exp Med; 1978 Feb; 147(2):409-21. PubMed ID: 624904
[TBL] [Abstract][Full Text] [Related]
26. Interaction of beta1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding.
Conrad DH; Carlo JR; Ruddy S
J Exp Med; 1978 Jun; 147(6):1792-1805. PubMed ID: 567241
[TBL] [Abstract][Full Text] [Related]
27. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes.
Mold C; Medof ME
Mol Immunol; 1985 May; 22(5):507-12. PubMed ID: 3848661
[TBL] [Abstract][Full Text] [Related]
28. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the alternative pathway of human complement by C1q.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1987 Sep; 24(9):987-93. PubMed ID: 2958692
[TBL] [Abstract][Full Text] [Related]
30. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
Medof ME; Prince GM; Mold C
Proc Natl Acad Sci U S A; 1982 Aug; 79(16):5047-51. PubMed ID: 6214790
[TBL] [Abstract][Full Text] [Related]
31. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
32. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
33. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
Kazatchkine MD; Fearon DT; Austen KF
J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
[No Abstract] [Full Text] [Related]
34. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
Nicholson-Weller A; Burge J; Fearon DT; Weller PF; Austen KF
J Immunol; 1982 Jul; 129(1):184-9. PubMed ID: 6211481
[No Abstract] [Full Text] [Related]
35. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
[TBL] [Abstract][Full Text] [Related]
36. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
37. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.
Maillet F; Kazatchkine MD; Glotz D; Fischer E; Rowe M
Mol Immunol; 1983 Dec; 20(12):1401-4. PubMed ID: 6558419
[TBL] [Abstract][Full Text] [Related]
38. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
[TBL] [Abstract][Full Text] [Related]
40. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
